Several ongoing clinical trials and preclinical studies (257–29) (Table 2) are currently investigating the role of different molecules in IPF pathogenesis to define their anti-proliferative and anti-fibrotic roles (Table 1) which might have good prospects even against lung cancer; these are the anti-IL-13 antibodies (QAX576 and Lebrikizumab), the anti-CCL2 antibodies (Carlumab and CNTO-888), the anti-TGF-β1 antibodies (Fresolimumab and GC1008), the anti-integrin αvβ6 antibodies (BG0011 and STX-100),and the integrin αvβ6 antagonist drugs (GSK3008348), etc. [251,252,253]. This evidence concerns the gene TGFB1 and lung carcinoma.